| abstract |
The present invention provides a method for effectively prolonging progression-free survival in a patient diagnosed with ovarian cancer who continues to receive a chemotherapeutic effective amount of an anti-VEGF antibody. Anti-angiogenesis for the treatment of ovarian cancer in which an anti-VEGF (vascular endothelial growth factor) antibody and a chemotherapeutic agent such as taxane, paclitaxel, docetaxel, paclitaxel protein-binding particles, platinum analog, carboplatin, gemcitabine are administered in combination Therapy. It is preferred that the anti-VEGF antibody is an antibody that binds to the same epitope as monoclonal anti-VEGF antibody A4.6.1 produced by hybridoma ATCC HB 10709. [Selection figure] None |